Actualización en hipertensión arterial pulmonar

C. R. Mejía Chew; S. Alcolea Batres; J. J. Ríos Blanco

doi:10.1016/j.rce.2016.04.002

Actualización en hipertensión arterial pulmonar

Translated title of the contribution: Update in pulmonary arterial hypertension

C. R. Mejía Chew, S. Alcolea Batres, J. J. Ríos Blanco

Research output: Contribution to journal › Short survey › peer-review

5 Scopus citations

Abstract

Pulmonary arterial hypertension is a rare and progressive disease that mainly affects the pulmonary arterioles (precapillary), regardless of the triggering aetiology. The prevalence of pulmonary hypertension and pulmonary arterial hypertension in Spain is estimated at 19.2 and 16 cases per million inhabitants, respectively. The diagnosis of pulmonary arterial hypertension is based on haemodynamic criteria (mean pulmonary artery pressure ≥25 mmHg, pulmonary capillary wedge pressure ≤15 mmHg and pulmonary vascular resistance >3 Wood units) and therefore requires the implementation of right cardiac catheterisation. Sequential therapy with a single drug has been used in clinical practice. However, recent European guidelines recommend combined initial therapy in some situations. This review conducts a critical update of our knowledge of this disease according to the latest guidelines and recommendations.

Translated title of the contribution	Update in pulmonary arterial hypertension
Original language	Spanish
Pages (from-to)	436-444
Number of pages	9
Journal	Revista Clinica Espanola
Volume	216
Issue number	8
DOIs	https://doi.org/10.1016/j.rce.2016.04.002
State	Published - Nov 1 2016

Keywords

Endothelin receptor antagonist
Phosphodiesterase type 5 inhibitors
Prostacyclin analogues
Pulmonary arterial hypertension
Pulmonary hypertension
Review

Access to Document

10.1016/j.rce.2016.04.002

Cite this

@article{53271f9e2a244af4b73ea8ee4d540778,

title = "Actualizaci{\'o}n en hipertensi{\'o}n arterial pulmonar",

abstract = "Pulmonary arterial hypertension is a rare and progressive disease that mainly affects the pulmonary arterioles (precapillary), regardless of the triggering aetiology. The prevalence of pulmonary hypertension and pulmonary arterial hypertension in Spain is estimated at 19.2 and 16 cases per million inhabitants, respectively. The diagnosis of pulmonary arterial hypertension is based on haemodynamic criteria (mean pulmonary artery pressure ≥25 mmHg, pulmonary capillary wedge pressure ≤15 mmHg and pulmonary vascular resistance >3 Wood units) and therefore requires the implementation of right cardiac catheterisation. Sequential therapy with a single drug has been used in clinical practice. However, recent European guidelines recommend combined initial therapy in some situations. This review conducts a critical update of our knowledge of this disease according to the latest guidelines and recommendations.",

keywords = "Endothelin receptor antagonist, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Pulmonary arterial hypertension, Pulmonary hypertension, Review",

author = "{Mej{\'i}a Chew}, {C. R.} and {Alcolea Batres}, S. and {R{\'i}os Blanco}, {J. J.}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Espa{\~n}a, S.L.U. and Sociedad Espa{\~n}ola de Medicina Interna (SEMI)",

year = "2016",

month = nov,

day = "1",

doi = "10.1016/j.rce.2016.04.002",

language = "Spanish",

volume = "216",

pages = "436--444",

journal = "Revista Clinica Espanola",

issn = "0014-2565",

number = "8",

}

TY - JOUR

T1 - Actualización en hipertensión arterial pulmonar

AU - Mejía Chew, C. R.

AU - Alcolea Batres, S.

AU - Ríos Blanco, J. J.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Pulmonary arterial hypertension is a rare and progressive disease that mainly affects the pulmonary arterioles (precapillary), regardless of the triggering aetiology. The prevalence of pulmonary hypertension and pulmonary arterial hypertension in Spain is estimated at 19.2 and 16 cases per million inhabitants, respectively. The diagnosis of pulmonary arterial hypertension is based on haemodynamic criteria (mean pulmonary artery pressure ≥25 mmHg, pulmonary capillary wedge pressure ≤15 mmHg and pulmonary vascular resistance >3 Wood units) and therefore requires the implementation of right cardiac catheterisation. Sequential therapy with a single drug has been used in clinical practice. However, recent European guidelines recommend combined initial therapy in some situations. This review conducts a critical update of our knowledge of this disease according to the latest guidelines and recommendations.

AB - Pulmonary arterial hypertension is a rare and progressive disease that mainly affects the pulmonary arterioles (precapillary), regardless of the triggering aetiology. The prevalence of pulmonary hypertension and pulmonary arterial hypertension in Spain is estimated at 19.2 and 16 cases per million inhabitants, respectively. The diagnosis of pulmonary arterial hypertension is based on haemodynamic criteria (mean pulmonary artery pressure ≥25 mmHg, pulmonary capillary wedge pressure ≤15 mmHg and pulmonary vascular resistance >3 Wood units) and therefore requires the implementation of right cardiac catheterisation. Sequential therapy with a single drug has been used in clinical practice. However, recent European guidelines recommend combined initial therapy in some situations. This review conducts a critical update of our knowledge of this disease according to the latest guidelines and recommendations.

KW - Endothelin receptor antagonist

KW - Phosphodiesterase type 5 inhibitors

KW - Prostacyclin analogues

KW - Pulmonary arterial hypertension

KW - Pulmonary hypertension

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84964950964&partnerID=8YFLogxK

U2 - 10.1016/j.rce.2016.04.002

DO - 10.1016/j.rce.2016.04.002

M3 - Short survey

C2 - 27156166

AN - SCOPUS:84964950964

SN - 0014-2565

VL - 216

SP - 436

EP - 444

JO - Revista Clinica Espanola

JF - Revista Clinica Espanola

IS - 8

ER -

Actualización en hipertensión arterial pulmonar

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this